These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 26354766

  • 1. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, Pilote L.
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, Park HJ, Kim Y, Cho JY, Kim MC, Sim DS, Yoon HJ, Yoon NS, Kim KH, Hong YJ, Kim JH, Ahn Y, Jeong MH, Park JC, Cho JG.
    Europace; 2017 Dec 01; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.
    Circulation; 2015 Jan 13; 131(2):157-64. PubMed ID: 25359164
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    Circ Cardiovasc Qual Outcomes; 2016 Mar 13; 9(2):126-34. PubMed ID: 26812933
    [Abstract] [Full Text] [Related]

  • 9. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.
    BMJ; 2015 Apr 24; 350():h1857. PubMed ID: 25910928
    [Abstract] [Full Text] [Related]

  • 10. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
    Lau WCY, Li X, Wong ICK, Man KKC, Lip GYH, Leung WK, Siu CW, Chan EW.
    J Thromb Haemost; 2017 Oct 24; 15(10):1923-1933. PubMed ID: 28748652
    [Abstract] [Full Text] [Related]

  • 11. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.
    Circ Cardiovasc Qual Outcomes; 2013 Sep 01; 6(5):567-74. PubMed ID: 23922182
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.
    J Am Coll Cardiol; 2013 Jun 04; 61(22):2264-73. PubMed ID: 23562920
    [Abstract] [Full Text] [Related]

  • 13. Does dabigatran interfere with intraablation heparinization?
    Sairaku A, Nakano Y, Kihara Y.
    Thromb Res; 2014 Sep 04; 134(3):742-3. PubMed ID: 25034323
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
    Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T.
    Pharmacoepidemiol Drug Saf; 2016 Nov 04; 25(11):1236-1244. PubMed ID: 27229855
    [Abstract] [Full Text] [Related]

  • 16. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S.
    Thromb Haemost; 2015 Nov 25; 114(6):1277-89. PubMed ID: 26446507
    [Abstract] [Full Text] [Related]

  • 17. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
    Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ.
    Circulation; 2019 Jun 18; 139(25):2846-2856. PubMed ID: 31046423
    [Abstract] [Full Text] [Related]

  • 18. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.
    Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ.
    Thromb Haemost; 2015 Mar 18; 113(3):625-32. PubMed ID: 25472710
    [Abstract] [Full Text] [Related]

  • 19. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
    Stabile E, Izzo R, Rozza F, Losi MA, Coscioni E, Trimarco B.
    High Blood Press Cardiovasc Prev; 2016 Jun 18; 23(2):115-22. PubMed ID: 27207360
    [Abstract] [Full Text] [Related]

  • 20. Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
    Huybrechts KF, Gopalakrishnan C, Bartels DB, Zint K, Gurusamy VK, Landon J, Schneeweiss S.
    Clin Pharmacol Ther; 2020 Jun 18; 107(6):1405-1419. PubMed ID: 31869437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.